Conteltinib

• CAT Number: I019114
• CAS Number: 1384860-29-0
• Molecular Formula: C₃₂H₄₅N₉O₃S
• Molecular Weight: 635.82
• Purity: ≥95%
• Target: FAK
• IUPAC Name: 2-[[2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-N-propan-2-ylbenzenesulfonamide
• InChI: InChI=1S/C32H45N9O3S/c1-22(2)38-45(42,43)29-8-6-5-7-27(29)34-31-25-11-14-33-30(25)36-32(37-31)35-26-10-9-24(21-28(26)44-4)40-15-12-23(13-16-40)41-19-17-39(3)18-20-41/h5-10,21-23,38H,11-20H2,1-4H3,(H3,33,34,35,36,37)
• InChIKey: NPJCURIANJMFEO-UHFFFAOYSA-N
• SMILES: CC(C)NS(=O)(=O)C1=CC=CC=C1NC2=NC(=NC3=C2CCN3)NC4=C(C=C(C=C4)N5CCC(CC5)N6CCN(CC6)C)OC

Conteltinib（Cat No.:I019114）is a small molecule inhibitor that targets multiple receptor tyrosine kinases, including c-Met (mesenchymal-epithelial transition factor), a key protein involved in cancer cell growth, survival, and metastasis. By inhibiting c-Met and other related kinases, Conteltinib has shown potential in the treatment of various cancers, particularly those with aberrant c-Met signaling, such as non-small cell lung cancer (NSCLC). Its mechanism of action aims to reduce tumor progression and improve treatment outcomes. Ongoing clinical trials are evaluating its safety, efficacy, and potential as part of targeted cancer therapies.